Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elisidepsin (PM02734), a cyclic depsipeptide, exhibits antineoplastic activity by inhibiting cancer cell proliferation and is under research for the treatment of various cancers, including non-small cell lung cancer (NSCLC) [1] [2] [3] [4].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Elisidepsin (PM02734), a cyclic depsipeptide, exhibits antineoplastic activity by inhibiting cancer cell proliferation and is under research for the treatment of various cancers, including non-small cell lung cancer (NSCLC) [1] [2] [3] [4]. |
In vitro | Elisidepsin, administered over 72 hours, suppresses the proliferation of diverse cancer cell types, demonstrating half-maximal inhibitory concentration (IC50) values starting from 0. |
In vivo | Elisidepsin administered intravenously at a dose of 100 µg/kg demonstrates efficacy in inhibiting lung cancer xenografts [3]. |
Synonyms | PM02734 |
Molecular Weight | 1477.87 |
Formula | C75H124N14O16 |
CAS No. | 681272-30-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Elisidepsin 681272-30-0 PM02734 inhibitor inhibit